MITCHELL CHARLOTTE JANE,KEELING SUZANNE ELAINE,PARR NIGEL JAMES,JONES PAUL SPENCER,HAMBLIN JULIE NICOLE,LE JOELLE
申请号:
NZ59607110
公开号:
NZ596071A
申请日:
2010.04.28
申请国别(地区):
NZ
年份:
2013
代理人:
摘要:
596071 Disclosed is a substituted indazole compound of formula (I) where the substituents are as disclosed in the specification. Examples of a compounds of formula (I) are: N-[5-[4-(5-{ [(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl} -1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide 6-(1H-indol-4-yl)-4-(5-{ [4-(1-methylethyl)-1-piperazinyl]methyl} -1,3-oxazol-2-yl)-1H-indazole and 2,4-difluoro-N-[5-[4-(5-{ [4-(1-methylethyl)-1-piperazinyl]methyl} -1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]benzenesulfonamide. Also disclosed are pharmaceutical compositions comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament. The medicament is useful in the treatment or use in the treatment of a disorder mediated by inappropriate PI3-kinase activity such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis and allergic rhinitis.